



**Table 6.2.1 Adjusted % Change from Baseline in Lipid Measures:  
 Protocol 27201-2 (Efficacy Evaluable Population)**

Lipid Measure	Treatment Week	Treatment Group	
		Pravastatin 5 mg BID (N=62)	Placebo (N=79)
%Δ LDL-C	Baseline (mg/dl)	228.0	231.3
	1	-13.3 <sup>c3</sup>	-0.3
	2	-18.8 <sup>c3</sup>	-0.6
	4	-19.6 <sup>c3</sup>	2.5
	8	-20.4 <sup>c3</sup>	2.0
	12	-17.5 <sup>c3</sup>	3.3
%Δ Total-C	Baseline (mg/dl)	304.0	306.9
	1	-10.0 <sup>c3</sup>	1.0
	2	-14.5 <sup>c3</sup>	-0.1
	4	-15.0 <sup>c3</sup>	2.3
	8	-15.3 <sup>c3</sup>	2.1
	12	-12.9 <sup>c3</sup>	3.7
%Δ HDL-C	Baseline (mg/dl)	47.0	45.5
	1	4.4 <sup>3</sup>	2.1
	2	3.5 <sup>a2</sup>	-1.1
	4	6.4 <sup>c3</sup>	-0.2
	8	6.7 <sup>a3</sup>	1.6
	12	5.6 <sup>a3</sup>	1.2
%Δ TG	Baseline (mg/dl)	125.2	133.1
	1	-10.5 <sup>b1</sup>	1.1
	2	-13.0 <sup>b3</sup>	1.5
	4	-16.6 <sup>c3</sup>	1.2
	8	-13.5 <sup>b3</sup>	0.6
	12	-11.0 <sup>b2</sup>	3.5

\* Sample size varied from week to week during study (range 53-62 for pravastatin, 67-79 for placebo)

<sup>a</sup> p ≤ 0.05; <sup>b</sup> p ≤ 0.01; <sup>c</sup> p ≤ 0.001 compared with placebo

<sup>1</sup> p ≤ 0.05; <sup>2</sup> p ≤ 0.01; <sup>3</sup> p ≤ 0.001 compared with baseline

**Table 6.2.2 Adjusted % Change from Baseline in Lipid Measures:  
 Protocol 27201-42 (Efficacy Evaluable Population)**

Lipid Measure	Treatment Week	Treatment Group	
		Pravastatin 10 mg QD (N=18-21)*	Placebo (N=31-39)*
%Δ LDL-C	Baseline (mg/dl)	210.5	222.0
	2	-21.2 <sup>c3</sup>	-1.2
	4	-27.2 <sup>c3</sup>	-4.7
	8	-22.4 <sup>c3</sup>	-3.7
%Δ Total-C	Baseline (mg/dl)	293.8	303.5
	2	-16.0 <sup>c3</sup>	-0.7
	4	-20.0 <sup>c3</sup>	-3.2
	8	-16.2 <sup>c3</sup>	-2.6
%Δ HDL-C	Baseline (mg/dl)	52.7	48.5
	2	4.1	-1.0
	4	4.1 <sup>a</sup>	-2.0
	8	6.6 <sup>1</sup>	0.5
%Δ TG	Baseline (mg/dl)	140.9	142.2
	2	-14.4 <sup>2</sup>	-1.0
	4	-13.1 <sup>1</sup>	-0.1
	8	-14.9 <sup>1</sup>	-4.3

<sup>a</sup> p ≤ 0.05; <sup>b</sup> p ≤ 0.01; <sup>c</sup> p ≤ 0.001 compared with placebo

<sup>1</sup> p ≤ 0.05; <sup>2</sup> p ≤ 0.01; <sup>3</sup> p ≤ 0.001 compared with baseline

\* Sample sizes varied from week to week during study. (range 18-21 for pravastatin, 31-39 for placebo)

**Table 6.2.3 Adjusted % Change From Baseline in Lipid Measures:  
 Protocol 27201-89 (Efficacy Evaluable Population)**

Lipid Measure	Treatment Week	Treatment Group	
		Pravastatin 10 mg QD (N=73)*	Placebo (N=37)*
%Δ LDL-C	Baseline (mg/dl)	187.4	188.3
	4	-18.6 <sup>1</sup>	-1.2
	8	-17.8 <sup>1</sup>	0.6
%Δ Total-C	Baseline (mg/dl)	265.8	265.7
	4	-13.0 <sup>1</sup>	0.1
	8	-12.3 <sup>1</sup>	1.5
%Δ HDL-C	Baseline (mg/dl)	47.8	48.2
	4	5.6	0.3
	8	4.5	4.9
%Δ TG	Baseline (mg/dl)	152.7	143.3
	4	-3.3	13.1
	8	0.3	7.1

<sup>1</sup> p ≤ 0.001 compared with baseline

\* Sample sizes varied from week to week during study (range 69-73 for pravastatin, 36-37 for placebo)